# Neurovance

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurovance

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.neurovance.com
- Total disclosed funding: $19M
- Latest round: Series A (Mar 24, 2015)
- Investors on record: 6

## About

Founded in 2011 and based in Cambridge, Massachusetts, Neurovance operates as a clinical stage neuroscience-focused company developing EB-1020 SR for adults who suffer from ADHD.

## Funding rounds

- Series A, Mar 24, 2015, $5.5M — Evercore Partners, Venture Investors, GBS Venture Partners, Novartis Venture Fund, Tekla Capital Management
- Series A, Apr 3, 2014, $6.3M — Venture Investors, GBS Venture Partners, Novartis Venture Fund, State of Wisconsin Investment Board, Tekla Capital Management
- Series A, Oct 15, 2013, $1.5M — Venture Investors, GBS Venture Partners, Novartis Venture Fund
- Series A, Apr 24, 2013, $3M — Venture Investors, GBS Venture Partners, Novartis Venture Fund
- Series A, Oct 11, 2012, $3M — Venture Investors, GBS Venture Partners, Novartis Venture Fund, State of Wisconsin Investment Board, Tekla Capital Management

## Investors

- Venture Investors — Series A
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- State of Wisconsin Investment Board — Series A
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series A
- Evercore Partners (https://capitalatlas.ai/funds/evercore-partners) — Series A